Registered number
11030393
PHARMAVACCS LTD
Filleted Accounts
31 October 2024
PHARMAVACCS LTD
Registered number: 11030393
Balance Sheet
as at 31 October 2024
Notes 2024 2023
£ £
Fixed assets
Intangible assets 3 38,746 49,400
Current assets
Debtors 4 4,637 7,200
Cash at bank and in hand 21,348 17,758
25,985 24,958
Creditors: amounts falling due within one year 5 (14,939) (39,830)
Net current assets/(liabilities) 11,046 (14,872)
Total assets less current liabilities 49,792 34,528
Creditors: amounts falling due after more than one year 6 (220,000) (290,000)
Net liabilities (170,208) (255,472)
Capital and reserves
Called up share capital 1,500 1,500
Profit and loss account (171,708) (256,972)
Shareholders' funds (170,208) (255,472)
The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.
The members have not required the company to obtain an audit in accordance with section 476 of the Act.
The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
The accounts have been prepared and delivered in accordance with the special provisions applicable to companies subject to the small companies regime. The profit and loss account has not been delivered to the Registrar of Companies.
AISHA SULEMAN
Director
Approved by the board on 3 March 2025
PHARMAVACCS LTD
Notes to the Accounts
for the year ended 31 October 2024
1 Accounting policies
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Turnover
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Intangible fixed assets
Intangible fixed assets are measured at cost less accumulative amortisation and any accumulative impairment losses.
Tangible fixed assets
Tangible fixed assets are measured at cost less accumulative depreciation and any accumulative impairment losses. Depreciation is provided on all tangible fixed assets, other than freehold land, at rates calculated to write off the cost, less estimated residual value, of each asset evenly over its expected useful life, as follows:
Plant and machinery over 10 years
Creditors
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
2 Employees 2024 2023
Number Number
Average number of persons employed by the company 2 2
3 Intangible fixed assets £
Research & Development:
Cost
At 1 November 2023 106,536
At 31 October 2024 106,536
Amortisation
At 1 November 2023 57,136
Provided during the year 10,654
At 31 October 2024 67,790
Net book value
At 31 October 2024 38,746
At 31 October 2023 49,400
Research & Development is being written off in equal annual instalments over its estimated economic life of 10 years.
4 Debtors 2024 2023
£ £
Trade debtors 4,637 7,200
5 Creditors: amounts falling due within one year 2024 2023
£ £
Other creditors 14,939 39,830
6 Creditors: amounts falling due after one year 2024 2023
£ £
Other Loans - Prestford Ltd 20,000 60,000
Directors Loans 200,000 230,000
220,000 290,000
7 Loans from directors
Description and conditions B/fwd Paid Repaid C/fwd
£ £ £ £
WAQQASS SHEIKH 16,800 100,000 (16,800) 100,000
AISHA SULEMAN 10,000 (10,000) -
SHATA ISMAIEL SALMAN AL JUBOORI 200,000 (100,000) 100,000
226,800 100,000 (126,800) 200,000
8 Controlling party
The company is under the ultimate control of Mr Waqqass Sheikh by virtue of him and his wife owning more than 50% of the issued share capital.
Share capital Nominal 2024 2024 2023
value Number £ £
Allotted, called up and fully paid:
Ordinary shares £1 each 1,500 1,000
Nominal Number Amount
value £
Shares issued during the period:
Ordinary shares £1 each - -
-
Shareholders Details Nominal Value Number Amount
Waqqass Sheikh £1.00 450 £450.00
Rizwana Sheikh £1.00 450 £450.00
Aisha Suleman £1.00 100 £100.00
Shatha Ismaiel Salman al Juboori £1.00 250 £250.00
Zabir Hakim £1.00 250 £250.00
9 Other information
PHARMAVACCS LTD is a private company limited by shares and incorporated in England. Its registered office is:
117b Withington Road
Manchester
M16 8EE
PHARMAVACCS LTD 11030393 false 2023-11-01 2024-10-31 2024-10-31 VT Final Accounts July 2024 AISHA SULEMAN No description of principal activity 11030393 2022-11-01 2023-10-31 11030393 core:WithinOneYear 2023-10-31 11030393 core:AfterOneYear 2023-10-31 11030393 core:ShareCapital 2023-10-31 11030393 core:RetainedEarningsAccumulatedLosses 2023-10-31 11030393 2023-11-01 2024-10-31 11030393 bus:PrivateLimitedCompanyLtd 2023-11-01 2024-10-31 11030393 bus:AuditExempt-NoAccountantsReport 2023-11-01 2024-10-31 11030393 bus:Director40 2023-11-01 2024-10-31 11030393 2 2023-11-01 2024-10-31 11030393 core:Goodwill 2023-11-01 2024-10-31 11030393 bus:Director1 2023-11-01 2024-10-31 11030393 bus:Director1 1 2023-11-01 2024-10-31 11030393 bus:Director2 2023-11-01 2024-10-31 11030393 bus:Director2 1 2023-11-01 2024-10-31 11030393 bus:Director3 2023-11-01 2024-10-31 11030393 bus:Director3 1 2023-11-01 2024-10-31 11030393 countries:England 2023-11-01 2024-10-31 11030393 bus:FRS102 2023-11-01 2024-10-31 11030393 bus:FilletedAccounts 2023-11-01 2024-10-31 11030393 2024-10-31 11030393 core:WithinOneYear 2024-10-31 11030393 core:AfterOneYear 2024-10-31 11030393 core:ShareCapital 2024-10-31 11030393 core:RetainedEarningsAccumulatedLosses 2024-10-31 11030393 core:Goodwill 2024-10-31 11030393 bus:Director1 1 2024-10-31 11030393 bus:Director2 1 2024-10-31 11030393 bus:Director3 1 2024-10-31 11030393 2023-10-31 11030393 core:Goodwill 2023-10-31 11030393 bus:Director1 1 2023-10-31 11030393 bus:Director2 1 2023-10-31 11030393 bus:Director3 1 2023-10-31 iso4217:GBP xbrli:pure